600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1
oleh: Mustafa Ozguroglu, Saadettin Kilickap, Igor Bondarenko, Ahmet Sezer, Mahmut Gümüş, Miranda Gogishvili, Xuanyao He, Giuseppe Gullo, Petra Rietschel, Ruben GW Quek
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2023-11-01 |
Deskripsi
No description available for this item.